Phathom Pharmaceuticals, Inc.
PHAT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001783183
No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Phathom Pharmaceuticals, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 133
- +16 vs. Q2 2025
- Shares held
- 62.3M
- +4.93M (+8.6%) vs. Q2 2025
- Total value
- $733.6M
- +$183.1M (+33.3%) vs. Q2 2025
- New holders
- 27
- 45 more added
- Sold out
- 11
- 28 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHAT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 161 | $782.1M |
| Q1 2026 | 174 | $765.5M |
| Q4 2025 | 173 | $1.03B |
| Q3 2025 | 133 | $733.6M |
| Q2 2025 | 117 | $550.5M |
| Q1 2025 | 137 | $401.4M |
| Q4 2024 | 144 | $541.2M |
| Q3 2024 | 133 | $1.31B |
| Q2 2024 | 114 | $598.6M |
| Q1 2024 | 114 | $588.2M |
| Q4 2023 | 117 | $503.3M |
| Q3 2023 | 110 | $452.7M |
| Q2 2023 | 103 | $612.6M |
| Q1 2023 | 84 | $219.7M |
| Q4 2022 | 87 | $316.6M |
| Q3 2022 | 94 | $334.3M |
| Q2 2022 | 94 | $230.0M |
| Q1 2022 | 82 | $349.1M |
| Q4 2021 | 83 | $562.0M |
| Q3 2021 | 84 | $819.8M |
| Q2 2021 | 79 | $843.6M |
| Q1 2021 | 84 | $919.2M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Phathom Pharmaceuticals, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 249,094 | $2.93M | 0.00% | +153,014+159.3% | Added |
| Morgan Stanley | 255,573 | $3.01M | 0.00% | +100,645+65.0% | Added |
| Susquehanna Portfolio Strategies, LLC | 267,962 | $3.15M | 0.05% | 00.0% | Unchanged |
| Walleye Capital LLC | 290,467 | $3.42M | 0.03% | +290,467 | New |
| Balyasny Asset Management LLC | 295,161 | $3.47M | 0.01% | +281,979+2,139.1% | Added |
| Avidity Partners Management LP | 306,000 | $3.60M | 0.82% | −758,500−71.3% | Reduced |
| Simplify Asset Management Inc. | 321,935 | $3.79M | 0.08% | −200,000−38.3% | Reduced |
| UBS Group AG | 338,360 | $3.98M | 0.00% | −81,113−19.3% | Reduced |
| Northern Trust Corp | 357,578 | $4.21M | 0.00% | −1,746−0.5% | Reduced |
| Charles Schwab Investment Management Inc | 365,904 | $4.31M | 0.00% | +5,744+1.6% | Added |
| SummitTX Capital, L.P. | 385,968 | $4.54M | 0.19% | +385,968 | New |
| StepStone Group LP | 422,085 | $4.97M | 2.34% | 00.0% | Unchanged |
| AIGH Capital Management LLC | 429,000 | $5.05M | 1.77% | +429,000 | New |
| Citadel Advisors LLC | 508,720 | $5.99M | 0.00% | +508,720 | New |
| Propel Bio Management, LLC | 552,927 | $6.51M | 6.51% | −370,000−40.1% | Reduced |
| Ameriprise Financial Inc | 554,590 | $6.53M | 0.00% | +373,739+206.7% | Added |
| Moore Capital Management, LP | 600,000 | $7.06M | 0.14% | 00.0% | Unchanged |
| State Street Corp | 1,053,591 | $12.4M | 0.00% | +204,167+24.0% | Added |
| Geode Capital Management, LLC | 1,088,910 | $12.8M | 0.00% | +18,983+1.8% | Added |
| Catalio Capital Management, LP | 1,128,521 | $13.3M | 2.46% | +456,231+67.9% | Added |
| GW&K Investment Management, LLC | 1,144,330 | $13.5M | 0.12% | +95,858+9.1% | Added |
| Catalys Pacific, LLC | 1,167,114 | $13.7M | 3.91% | 00.0% | Unchanged |
| Wasatch Advisors Inc | 1,537,218 | $18.1M | 0.10% | +75,323+5.2% | Added |
| 683 Capital Management, LLC | 1,820,380 | $21.4M | 1.95% | −284,620−13.5% | Reduced |
| NEA Management Company, LLC | 1,960,169 | $23.1M | 1.27% | 00.0% | Unchanged |
| Ensign Peak Advisors, Inc | 2,503,344 | $29.5M | 0.05% | −16,628−0.7% | Reduced |
| Vanguard Group Inc | 3,215,572 | $37.8M | 0.00% | +428,261+15.4% | Added |
| BlackRock, Inc. | 3,402,324 | $40.0M | 0.00% | +86,976+2.6% | Added |
| Carlyle Group Inc. | 3,496,808 | $41.1M | 0.95% | 00.0% | Unchanged |
| Invesco Ltd. | 3,864,971 | $45.5M | 0.01% | −275,101−6.6% | Reduced |
| Millennium Management LLC | 5,081,451 | $59.8M | 0.05% | +2,830,954+125.8% | Added |
| Medicxi Ventures Management (Jersey) Ltd | 7,464,572 | $87.9M | 11.80% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 12,466,489 | $146.7M | 4.40% | 00.0% | Unchanged |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −306,399−100.0% | Sold out |
| State of Wisconsin Investment Board | 0 | $0 | 0.00% | −90,781−100.0% | Sold out |
| Diadema Partners LP | 0 | $0 | 0.00% | −40,294−100.0% | Sold out |
| Nebula Research & Development LLC | 0 | $0 | 0.00% | −37,937−100.0% | Sold out |
| Voya Investment Management LLC | 0 | $0 | 0.00% | −11,823−100.0% | Sold out |
| Entropy Technologies, LP | 0 | $0 | 0.00% | −11,600−100.0% | Sold out |
| ProShare Advisors LLC | 0 | $0 | 0.00% | −11,265−100.0% | Sold out |
| Staley Capital Advisers Inc | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Persistent Asset Partners Ltd | 0 | $0 | 0.00% | −9,421−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −2,718−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −11−100.0% | Sold out |